CompletedPhase 1

Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)

Canada24 participantsStarted 2025-12-04

Plain-language summary

Drug-drug interaction study between Ethinyl Estradioll/Levonorgestrel and Bemnifosbuvir/Ruzasvir

Who can participate

Age range18 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy post-menopausal or hormonally sterile female * Minimum body weight of 50 kg and body mass index (BMI) of 18.0-30 kg/m2. * Willing to comply with the study requirements and to provide written informed consent. Exclusion Criteria: * Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2. * Abuse of alcohol or drugs. * Use of other investigational drugs within 28 days of dosing. * Concomitant use of prescription medications, or systemic over-the-counter medications. * Other clinically significant medical conditions or laboratory abnormalities.

What they're measuring

PK of EE/LNG (Cmax)

Timeframe: Day 1,15

PK of EE/LNG (AUC)

Timeframe: Day 1,15

Trial details

NCT IDNCT07272889

SponsorAtea Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-02-17

View on ClinicalTrials.gov More Healthy Volunteer Study trials